Biosimilars
•11 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (11)
| Company | Market Cap | Price |
|---|---|---|
|
ABT
Abbott Laboratories
Abbott's biosimilars pipeline signals growth potential in biosimilar therapeutics, aligning with the Biosimilars investable theme.
|
$217.70B |
$125.42
+0.01%
|
|
AMGN
Amgen Inc.
Amgen maintains a significant Biosimilars portfolio with multiple launches since 2018.
|
$177.60B |
$331.94
-2.42%
|
|
VTRS
Viatris Inc.
Viatis pursues biosimilar opportunities alongside its generics portfolio.
|
$12.74B |
$11.00
+2.23%
|
|
RDY
Dr. Reddy's Laboratories Limited
Significant emphasis on biosimilar development and commercialization.
|
$11.84B |
$14.19
+0.32%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Amneal is expanding into biosimilars, a core diversification from traditional generics.
|
$3.83B |
$12.18
+2.01%
|
|
OGN
Organon & Co.
Biosimilars portfolio (Hadlima, Renflexis, Ontruzant, Tofidence) represents a major product line.
|
$1.86B |
$7.41
+3.71%
|
|
HROW
Harrow Health, Inc.
Strategic biosimilars portfolio in ophthalmology (BYOOVIZ, OPUVIZ) with Samsung Bioepis.
|
$1.69B |
$45.90
-1.87%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Amphastar is advancing biosimilar programs (AMP-004) and positions biosimilars as a core growth pillar.
|
$1.24B |
$26.77
-1.40%
|
|
KMDA
Kamada Ltd.
Biosimilar product distribution is a key existing business line for Kamada's expanded portfolio.
|
$406.96M |
$7.04
-0.98%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RT-111 and RT-105 include ustekinumab and adalimumab biosimilars, fitting the biosimilars category.
|
$114.27M |
$1.62
+3.18%
|
|
SCNX
Scienture Holdings, Inc.
SCN-106 is described as a potential biosimilar, fitting the Biosimilars investable theme.
|
$9.84M |
$0.61
+0.64%
|
Loading company comparison...
Loading industry trends...
Loading research report...
